In a quiet but consequential shift in the world of medical policy, Britain’s largest doctors’ union has effectively admitted what many critics long suspected: the evidence for using puberty blockers on gender-distressed children is lacking, contrary to activists’ claims.
The admission by the British Medical Association (BMA) comes after the 2024 release of the landmark, government-mandated Cass Review, led by Dr. Hilary Cass, cast doubt on the medical efficacy and safety of medically transitioning teens and prepubescent children.
After two years of internal review, the BMA’s fierce opposition to the Cass Review has shifted to conceding that the evidence base for gender transitioning was weak, uncertain, and the “first, do no harm” principle should have guided decisions more carefully from the start—just as Cass’s report suggested.
Trevor Stammers, former chair of the Christian Medical Fellowship, put it bluntly: “Whenever ideology prevails over evidence, people must eventually face up to reality. Proverbs 24:28 cautions, ‘Do not testify against your neighbor without cause.’” The BMA’s “U-turn,” he noted, shows that attacks on Cass ultimately failed to discredit her core findings.
For years, radical gender ideology has prevailed in the U.K. Formerly, the Tavistock and Portman NHS Foundation Trust’s Gender Identity Development Service stood as the UK’s sole centralized hub for treating young people with gender dysphoria. Referrals exploded—from a handful in the early 2010s to thousands, which included up to 70 children as young as 3 and 4 years old.
Cass’s independent review, commissioned by NHS England and published in April 2024, painted a sobering picture. It found:
- Shockingly poor-quality evidence supporting the use of puberty blockers and cross-sex hormones on minors.
- High rates of co-occurring mental health issues like depression, anxiety, autism and ADHD among referred youth.
- A lack of long-term data on benefits versus known and potential harms.
- A service model that was unsustainable and not sufficiently evidence-based.
The Cass Review, which used data from 113,000 children over the course of four years, highlighted how many of these young people have complex psychosocial needs that puberty blockers—powerful, experimental drugs with significant side effects on bone density, fertility, and cognitive development—don’t magically resolve.
Cass ultimately offered over 30 recommendations on how to better address gender dysphoria in young people. What followed the release of her report is that the Tavistock clinic closed, puberty blockers were banned for minors in England, and a more holistic, cautious approach emphasizing mental health took center stage.
But in July 2024, the medical association’s council aggressively pushed back and voted to “oppose the implementation” of the review. They labeled Cass’s recommendations “unsubstantiated,” called for the ban to be lifted, and even planned a public critique. The move drew sharp internal backlash from rank-and-file doctors who saw it as prioritizing ideology over patient safety—specifically referring to it as a “waste of money and time.”
Notably, the BMA stood apart as a standalone within the major UK medical establishment in its opposition to Cass’s findings, even as researchers in other European countries were beginning to raise similar concerns about pediatric treatment of gender dysphoria.
Fast forward to 2026, after its internal evaluation which was originally intended for release in January 2025, the BMA has now published the 36-page report, “Cass Review: Evidence, Interpretation, and Implementation.” Professor David Strain, chair of the BMA’s board of science and lead author of the report, told The Times of London that Cass “has been vindicated in the way she approached the data.” When pressed by the paper on any fundamental disagreements BMA now has with Cass’s recommendations, he said he couldn’t name even one.
Strain noted how Cass “approached an area of significant uncertainty with that prime rule of medicine, of ‘first, do no harm.’” The union now acknowledges the “limited and uncertain” evidence for puberty suppression—a major reversal from their earlier stance.
As reactions pour in, many say this isn’t just bureaucratic infighting but about protecting vulnerable children during a period of explosive identity confusion influenced by social media, peer groups, and rapid-onset cases never seen in previous generations.
That said, the BMA isn’t fully aligned with the government’s stricter ban on puberty blockers, arguing it poses “a threat to the autonomy of a doctor.” The organization still sees any government action to limit or ban the harmful drugs as political rather than medical. Strain further argued that while puberty blockers shouldn’t be “freely available,” they should remain available through “appropriately trained specialists.” The BMA remains committed to promoting LGBT-related ideology in the medical field.
Nonetheless, Christians and other cultural conservatives have welcomed BMA’s apparent shift toward evidence and restraint.
Meanwhile, observers are watching to see if the weight of the Cass Review’s findings—as well as other countries like Sweden and Finland moving away from the “affirmation-at-all-costs” model that dominated for a decade— has a similar influence on such practices in the United States.
